McKesson Corporation
MCK
Kedudukan dalam Saham
#189
McKesson Corporation is a prominent global provider of healthcare services,... McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
Harga Saham
$1,011.60
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$117.94B
Perubahan (1 hari)
0.64%
Perubahan (1 tahun)
28.40%
Negara
US
Perdagangan McKesson Corporation (MCK)
Kategori
Healthcare
Nisbah P/E bagi McKesson Corporation (MCK)
Nisbah P/E pada October 2026 TTM: 26.02
Menurut laporan kewangan dan harga saham terkini McKesson Corporation, nisbah P/E semasa (TTM) ialah 26.02. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 23.80.
Sejarah nisbah P/E bagi McKesson Corporation dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 26.02 | 0.00% |
| 2025 | 26.02 | 9.31% |
| 2024 | 23.80 | 68.68% |
| 2023 | 14.11 | -66.28% |
| 2022 | 41.85 | -706.47% |
| 2021 | -6.90 | -125.37% |
| 2020 | 27.20 | -96.04% |
| 2019 | 686.13 | 56.89% |
| 2018 | 437.33 | 6,817.88% |
| 2017 | 6.32 | -60.53% |
| 2016 | 16.02 | -54.95% |
| 2015 | 35.55 | 11.06% |
| 2014 | 32.01 | 68.89% |
| 2013 | 18.96 | 23.18% |
| 2012 | 15.39 | -14.73% |
| 2011 | 18.05 | 28.94% |
| 2010 | 14.00 | 19.55% |
| 2009 | 11.71 | -23.94% |
| 2008 | 15.39 | -15.02% |
| 2007 | 18.12 | -16.19% |
| 2006 | 21.61 | -130.58% |
| 2005 | -70.69 | -623.74% |
| 2004 | 13.50 | 3.94% |
| 2003 | 12.99 | -49.58% |
| 2002 | 25.75 | -116.43% |
| 2001 | -156.79 | -2,020.83% |
| 2000 | 8.16 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| - | - |
US
|
|
| 34.08 | 30.96% |
US
|
|
| - | - |
US
|
|
| 45.62 | 75.31% |
AU
|
|
| 24.73 | -4.97% |
US
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.